medigraphic.com

2018, Number 3

<< Back Next >>

Rev Hosp Jua Mex 2018; 85 (3)

Voriconazole induced Stevens-Johnson syndrome: a case report

Willeford BT, González-Ibarra FP, Ortega VM

Language: English
References: 12
Page: 173-175
PDF size: 196.85 Kb.


ABSTRACT

Stevens-Johnson syndrome is a life-threatening skin disorder which is known to occur associated with a variety of medications. One of these classes of medications is antifungals and the mechanism is known to be mediated through altering gene expression of cytochrome P450 (CYP) 26 isoforms. To the best of our knowledge, this is the first reported case of Stevens-Johnson syndrome induced by voriconazole.


REFERENCES

  1. Mawson AR, Eriator I, Karre S. Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN): could retinoids play a causative role? Med Sci Monit 2015; 21: 133-43.

  2. Harr T, French LE. Toxic epidermal necrolysis and Stevens-Johnson syndrome. Orphanet J Rare Dis 2010; 5: 39.

  3. Greer ND. Voriconazole: the newest triazole antifungal agent. Proc (Bayl Univ Med Cent) 2003; 16(2): 241-8.

  4. Niwa, T, Imagawa Y, Yamazaki H. Drug interactions between nine antifungal agents and drugs metabolized by human cytochromesP450. Curr Drug Metab 2014; 15(7): 651-79.

  5. Martinez-Cabriales S, Gómez-Flores M, Ocampo-Candiani J. News in severe clinical adverse drug reactions: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN)]. Gac Med Mex 2015; 151(6): 777-87.

  6. Willis Z, Boyd AS, Di Pentima MC. Phototoxicity, Pseudoporphyria, and photo-onycholysis due to voriconazole in a pediatric patient with leukemia and invasive aspergillosis. J Pediatric Infect Dis Soc 2015; 4(2): e22-4.

  7. Malani AN, Aronoff DM. Voriconazole-induced photosensitivity. Clin Med Res 2008; 6(2): 83-5.

  8. Lat A, Thompson GR 3rd. Update on the optimal use of voriconazole for invasive fungal infections. Infect Drug Resist 2011; 4: 43-53.

  9. Brazzola P, Rossi MR. High weekly doses of liposomal amphotericin B as secondary prophylaxis after cerebral aspergillosis in a paediatric patient. Med Mycol Case Rep 2014; 3: 1-3.

  10. Rosen AC, Balagula Y, Raisch DW, Garg V, Nardone B, Larsen N, et al. Life-threatening dermatologic adverse events in oncology. Anticancer Drugs 2014; 25(2): 225-34.

  11. Curiglana G, Formica V, De Pas T, Spitaleri G, Pietri E, Fazio N, et al. Life-threatening toxic epidermal necrolysis during voriconazole therapy for invasive aspergillosis after chemotherapy. Ann Oncol 2006; 17(7): 1174-5.

  12. Gomulka J, Wilson BD, Joyce JC. Toxic epidermal necrolysis due to voriconazole: case report and review. Dermatol Online J 2104; 20(9). pii: 13030/qt2pt32578.




2020     |     www.medigraphic.com